CI 10-Q Quarterly Report March 31, 2022 | Alphaminr

Effective Date August 11, 2021

These terms and conditions govern your use of the website alphaminr.com and its related services.

These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.

Subscription

Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.

Fees

We will provide you with advance notice of any change in fees.

Usage

You represent that you are of legal age to form a binding contract. You are responsible for any activity associated with your account. The account can be logged in at only one computer at a time.
The Services are intended for your own individual use. You shall only use the Services in a manner that complies with all laws. You may not use any automated software, spider or system to scrape data from Alphaminr.

Limitation of Liability

Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.

TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.

If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.

CIGNA CORP

10-Qs and 10-Ks

10-Q	Quarter ended March 31, 2025
10-K	Fiscal year ended Dec. 31, 2024
10-Q	Quarter ended Sept. 30, 2024
10-Q	Quarter ended June 30, 2024
10-Q	Quarter ended March 31, 2024
10-K	Fiscal year ended Dec. 31, 2023
10-Q	Quarter ended Sept. 30, 2023
10-Q	Quarter ended June 30, 2023
10-Q	Quarter ended March 31, 2023
10-K	Fiscal year ended Dec. 31, 2022
10-Q	Quarter ended Sept. 30, 2022
10-Q	Quarter ended June 30, 2022
10-Q	Quarter ended March 31, 2022
10-K	Fiscal year ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-Q	Quarter ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-K	Fiscal year ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-Q	Quarter ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-K	Fiscal year ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-Q	Quarter ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-K	Fiscal year ended Dec. 31, 2018

PROXIES

DEF 14A	Filed on March 14, 2025
DEF 14A	Filed on March 15, 2024
DEF 14A	Filed on March 17, 2023
DEF 14A	Filed on March 18, 2022
DEF 14A	Filed on March 19, 2021
DEF 14A	Filed on March 13, 2020
DEF 14A	Filed on March 15, 2019

TABLE OF CONTENTS

Part Iprint Item 1. Financial Statementsprint Note 1 Description Of Businessprint Note 2 Summary Of Significant Accounting Policiesprint Note 3 Accounts Receivable, Netprint Note 4 Mergers, Acquisitions and Divestituresprint Note 5 Assets and Liabilities Of Businesses Held For Saleprint Note 6 Earnings Per Share ("eps")print Note 7 Debtprint Note 8 Common and Preferred Stockprint Note 9 Insurance and Contractholder Liabilitiesprint Note 10 Reinsuranceprint Note 11 Investmentsprint Note 12 Fair Value Measurementsprint Note 13 Variable Interest Entitiesprint Note 14 Accumulated Other Comprehensive Income (loss) ("aoci")print Note 15 Organizational Efficiency Planprint Note 16 Leasesprint Note 17 Income Taxesprint Note 18 Contingencies and Other Mattersprint Note 19 Segment Informationprint Item 3. Quantitative and Qualitative Disclosures About Market Riskprint Item 4. Controls and Proceduresprint Part II. Other Informationprint Part IIprint Item 1. Legal Proceedingsprint Item 1A. Risk Factorsprint Item 2. Unregistered Sales Of Equity Securities and Use Of Proceedsprint Item 6. Exhibitsprint

Exhibits

31.1 Certification of Chief Executive Officer of Cigna Corporation pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 Filed herewith. 31.2 Certification of Chief Financial Officer of Cigna Corporation pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 Filed herewith. 32.1 Certification of Chief Executive Officer of Cigna Corporation pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350 Furnished herewith. 32.2 Certification of Chief Financial Officer of Cigna Corporation pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C. Section 1350 Furnished herewith.

* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.

FUND	NUMBER OF SHARES	VALUE ($)	PUT OR CALL

DIRECTORS	AGE	BIO	OTHER DIRECTOR MEMBERSHIPS

Customers

Customer name	Ticker
Truist Financial Corporation	TFC
Fidelity National Financial, Inc.	FNF
KeyCorp	KEY
Old Republic International Corporation	ORI
Stewart Information Services Corporation	STC
Tenet Healthcare Corporation	THC

Suppliers

Supplier name	Ticker
Abbott Laboratories	ABT
AbbVie Inc.	ABBV
Bristol-Myers Squibb Company	BMY
Johnson & Johnson	JNJ
Merck & Co., Inc.	MRK
Pfizer Inc.	PFE
Amgen Inc.	AMGN

Owner	Position	Direct Shares	Indirect Shares